RAPT Therapeutics Inc

NASDAQ RAPT

Data sourced from

and

Download Data

RAPT Therapeutics Inc Days in Inventory for the Trailing 12 Months (TTM) ending March 31, 2024

RAPT Therapeutics Inc Days in Inventory is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The days in inventory ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing 365 by the ratio of cost of revenue to the average of inventory and other current assets. This ratio indicates the efficiency of inventory management and the company's ability to convert inventory into sales within a specific period. A lower number of days in inventory is generally preferable.

NASDAQ: RAPT

RAPT Therapeutics Inc

CEO	Dr. Brian Russell Wong M.D., Ph.D.
IPO Date	Oct. 31, 2019
Location	United States
Headquarters	561 Eccles Avenue, South San Francisco, CA, United States, 94080
Employees	126
Sector	Healthcare
Industry	Biotechnology

Description

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Key trends